The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
1
If a conflict arises between a Clinical Payment and Coding Policy and any plan
document under which a member is entitled to Covered Services, the plan
document will govern. If a conflict arises between a CPCP and any provider contract
pursuant to which a provider participates in and/or provides Covered Services to
eligible member(s) and/or plans, the provider contract will govern. “Plan documents”
include, but are not limited to, Certificates of Health Care Benefits, benefit booklets,
Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue
Shield of TX may use reasonable discretion interpreting and applying this policy to
services being delivered in a particular case. Blue Cross and Blue Shield of TX has
full and final discretionary authority for their interpretation and application to the
extent provided under any applicable plan documents.
Providers are responsible for submission of accurate documentation of services
performed. Providers are expected to submit claims for services rendered using
valid code combinations from Health Insurance Portability and Accountability Act
approved code sets. Claims should be coded appropriately according to industry
standard coding guidelines including, but not limited to: Uniform Billing Editor,
American Medical Association, Current Procedural Terminology, CPT® Assistant,
Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug
Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid
Services National Correct Coding Initiative Policy Manual, CCI table edits and other
CMS guidelines.
Claims are subject to the code edit protocols for services/procedures billed. Claim
submissions are subject to claim review including but not limited to, any terms of
benefit coverage, provider contract language, medical policies, clinical payment and
coding policies as well as coding software logic. Upon request, the provider is urged
to submit any additional documentation.
Vitamin D Testing
Policy Number: CPCPLAB003
Version 1.0
Approval Date: Sept. 13, 2024
Plan Effective Date: Jan. 1, 2025 (Blue Cross and Blue Shield of Texas Only)
Description
The plan has implemented certain lab management reimbursement criteria. Not all
requirements apply to each product. Providers are urged to review Plan documents
for eligible coverage for services rendered.
Blue Cross and Blue Shield of Texas, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company,
an Independent Licensee of the Blue Cross and Blue Shield Association
Page 2
2
Reimbursement Information:
1. For individuals with an underlying disease or condition which is specifically
associated with vitamin D deficiency or decreased bone density (see Note 1) or
for individuals suspected of hypervitaminosis of Vitamin D, 25-hydroxyvitamin D
serum testing may be reimbursable.
2. As part of the total 25-hydroxyvitamin D analysis, testing for D2 and D3 fractions
of 25-hydroxyvitamin D may be reimbursable.
3. For individuals who have documented vitamin D deficiency, repeat testing for
serum 25-hydroxyvitamin D at least 12 weeks after the initiation of vitamin D
supplementation may be reimbursable with the following restrictions:
a. Repeat testing for monitoring of supplementation therapy should not exceed
2 testing instances per year until the therapeutic goal is achieved.
b. Once therapeutic range has been reached, annual testing, may be
reimbursable.
4. For the evaluation or treatment of conditions that are associated with defects in
vitamin D metabolism (see Note 2), 1,25-dihydroxyvitamin D serum testing may
be reimbursable.
5. The following testing is not reimbursable:
a. Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D
deficiency.
b. Routine screening for vitamin D deficiency with serum testing in
asymptomatic individuals and/or during general encounters
Note 1: Indications that support reimbursement for serum measurement of
25-hydroxyvitamin D are as follows:
A. Biliary cirrhosis and other specified disorders of the biliary tract
B. Blind loop syndrome
C. Celiac Disease
D. Coronary artery disease in individuals where risk of disease progression is
being considered against benefits of chronic vitamin D and calcium therapy
E. Dermatomyositis
F. Eating disorders
G. Having undergone, or for those who have been scheduled for, bariatric
procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, or
biliopancreatic diversion with or without duodenal switch
H. Hypercalcemia, hypocalcemia. or other disorders of calcium metabolism
I. Hyperparathyroidism or hypoparathyroidism
J. Individuals receiving hyperalimentation
K. Intestinal malabsorption
L. Liver cirrhosis
Page 3
3
M. Long term use of anticonvulsants, glucocorticoids and other medications
known to lower vitamin D levels
N. Malnutrition
O. Myalgia and other myositis not specified
P. Myopathy related to endocrine diseases
Q. Neoplastic hematologic disorders
R. Obesity
S. Osteogenesis imperfecta
T. Osteomalacia
U. Osteopetrosis
V. Osteoporosis
W. Pancreatic steatorrhea
X. Primary or miliary tuberculosis
Y. Psoriasis
Z. Regional enteritis
AA. Renal, ureteral, or urinary calculus
BB. Rickets
CC. Sarcoidosis
DD. Stage III-V Chronic Kidney Disease and End Stage Renal Disease
EE. Systemic lupus erythematosus
Note 2: Indications that support reimbursement for serum testing of 1,25-
dihydroxyvitamin D are as follows:
A. Disorders of calcium metabolism
B. Familial hypophosphatemia
C. Fanconi syndrome
D. Hyperparathyroidism or hypoparathyroidism
E. Individuals receiving hyperalimentation
F. Neonatal hypocalcemia
G. Osteogenesis imperfecta
H. Osteomalacia
I. Osteopetrosis
J. Primary or miliary tuberculosis
K. Renal, ureteral, or urinary calculus
L. Rickets
M. Sarcoidosis
N. Stage III-V Chronic Kidney Disease and End Stage Renal Disease
Procedure Codes
The following is not an all-encompassing code list. The inclusion of a code does not
guarantee it is a covered service or eligible for reimbursement.
Codes
82306, 82652, 0038U
Page 4
4
References:
ACOG. (2011). ACOG Committee Opinion No. 495: Vitamin D: Screening and
supplementation during pregnancy. Obstet Gynecol, 118(1), 197-198.
https://doi.org/10.1097/AOG.0b013e318227f06b
Annema, W., Nowak, A., von Eckardstein, A., & Saleh, L. (2018). Evaluation of the new
restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient
and vitamin D-supplemented individuals. J Clin Lab Anal, 32(4), e22328.
https://doi.org/10.1002/jcla.22328
Aspray, T. J., Bowring, C., Fraser, W., Gittoes, N., Javaid, M. K., Macdonald, H., Patel,
S., Selby, P., Tanna, N., & Francis, R. M. (2014). National Osteoporosis Society
vitamin D guideline summary. Age Ageing, 43(5), 592-595.
https://doi.org/10.1093/ageing/afu093
Avenell, A., Bolland, M. J., & Grey, A. (2018). 25-Hydroxyvitamin D - Should labs be
measuring it? Ann Clin Biochem, 4563218796858.
https://doi.org/10.1177/0004563218796858
Awumey, E. M., Mitra, D. A., Hollis, B. W., Kumar, R., & Bell, N. H. (1998). Vitamin D
metabolism is altered in Asian Indians in the southern United States: a clinical
research center study. J Clin Endocrinol Metab, 83(1), 169-173.
https://doi.org/10.1210/jcem.83.1.4514
Bolland, M. J., Grey, A., & Avenell, A. (2018). Effects of vitamin D supplementation on
musculoskeletal health: a systematic review, meta-analysis, and trial sequential
analysis. Lancet Diabetes Endocrinol. https://doi.org/10.1016/s2213-
8587(18)30265-1
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris,
S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., Pessah-Pollack, R., McClung, M.,
Wimalawansa, S. J., & Watts, N. B. (2020). AMERICAN ASSOCIATION OF CLINICAL
ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL
PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF
POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract, 26(Suppl 1), 1-
46. https://doi.org/10.4158/gl-2020-0524suppl
CDC. (2017). VDSCP: Vitamin D Standardization-Certification Program. VDSCP:
Vitamin D Standardization-Certification Program
CDC. (2019). CDC Vitamin D Standardization-Certification Program.
https://www.cdc.gov/labstandards/pdf/hs/CDC_Certified_Vitamin_D_Procedures-
508.pdf
CDC. (2023). Facts: Falls Are Serious and Costly. https://www.cdc.gov/falls/facts.html
Chapuy, M. C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., Garnero,
P., & Meunier, P. J. (2002). Combined calcium and vitamin D3 supplementation in
elderly women: confirmation of reversal of secondary hyperparathyroidism and
hip fracture risk: the Decalyos II study. Osteoporos Int, 13(3), 257-264.
https://doi.org/10.1007/s001980200023
Crowe, F. L., Thayakaran, R., Gittoes, N., Hewison, M., Thomas, G. N., Scragg, R., &
Nirantharakumar, K. (2019). Non-linear associations of 25-hydroxyvitamin D
Page 5
5
concentrations with risk of cardiovascular disease and all-cause mortality:
Results from The Health Improvement Network (THIN) database. J Steroid
Biochem Mol Biol, 195, 105480. https://doi.org/10.1016/j.jsbmb.2019.105480
Dawson-Hughes, B. (2023, May 16). Causes of vitamin D deficiency and resistance.
Wolters Kluwer. https://www.uptodate.com/contents/causes-of-vitamin-d-
deficiency-and-resistance
Dawson-Hughes, B. (2023, September 30, 2023). Vitamin D deficiency in adults:
Definition, clinical manifestations, and treatment. UptoDate.
https://www.uptodate.com/contents/vitamin-d-deficiency-in-adults-definition-
clinical-manifestations-and-treatment
Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997). Effect of calcium
and vitamin D supplementation on bone density in men and women 65 years of
age or older. N Engl J Med, 337(10), 670-676.
https://doi.org/10.1056/nejm199709043371003
Dedeoglu, M., Garip, Y., & Bodur, H. (2014). Osteomalacia in Crohn's disease. Arch
Osteoporos, 9, 177. https://doi.org/10.1007/s11657-014-0177-0
Ebell, M. H. (2019). Vitamin D Is Not Effective as Primary Prevention of
Cardiovascular Disease or Cancer. Am Fam Physician, 100(6), 374.
El Amrousy, D., El Ashry, H., Hodeib, H., & Hassan, S. (2021). Vitamin D in Children
With Inflammatory Bowel Disease: A Randomized Controlled Clinical Trial. J Clin
Gastroenterol, 55(9), 815-820. https://doi.org/10.1097/MCG.0000000000001443
Fletcher, J., Cooper, S. C., Ghosh, S., & Hewison, M. (2019). The Role of Vitamin D in
Inflammatory Bowel Disease: Mechanism to Management. Nutrients, 11(5).
https://doi.org/10.3390/nu11051019
Glendenning, P., & Inderjeeth, C. A. (2012). Vitamin D: methods of 25 hydroxyvitamin
D analysis, targeting at risk populations and selecting thresholds of treatment.
Clin Biochem, 45(12), 901-906. https://doi.org/10.1016/j.clinbiochem.2012.04.002
Golden, N. H., & Abrams, S. A. (2014). Optimizing bone health in children and
adolescents. Pediatrics, 134(4), e1229-1243. https://doi.org/10.1542/peds.2014-
2173
Goulart, R. A., & Barbalho, S. M. (2022). Can vitamin D induce remission in patients
with inflammatory bowel disease? Ann Gastroenterol, 35(2), 140-149.
https://doi.org/10.20524/aog.2022.0692
Granado-Lorencio, F., Blanco-Navarro, I., & Perez-Sacristan, B. (2016). Criteria of
adequacy for vitamin D testing and prevalence of deficiency in clinical practice.
Clin Chem Lab Med, 54(5), 791-798. https://doi.org/10.1515/cclm-2015-0781
Hao, L., Carson, J. L., Schlussel, Y., Noveck, H., & Shapses, S. A. (2020). Vitamin D
deficiency is associated with reduced mobility after hip fracture surgery: a
prospective study. The American Journal of Clinical Nutrition, 112(3), 613-618.
https://doi.org/10.1093/ajcn/nqaa029
Holick, M. F. (2009). Vitamin D status: measurement, interpretation, and clinical
application. Ann Epidemiol, 19(2), 73-78.
https://doi.org/10.1016/j.annepidem.2007.12.001
Holick, M. F. (2020). A call for action: standard of care guidelines to assess vitamin D
status are needed for patients with hip fracture. Am J Clin Nutr, 112(3), 507-509.
https://doi.org/10.1093/ajcn/nqaa202